Digital biomarker can identify which cases of mild cognitive impairment will develop into Alzheimer’s so that early interventions can be put in place to prevent the onset of the disease.
Tara M. DeSilva from the Department of Neurosciences, Cleveland Clinic, walks us through regenerative therapies for multiple sclerosis, including comment on clues from studying normal brain development.
One of JPND’s key objectives is to fortify its work in brain health partnerships in Europe to better combat the challenges of neurodegenerative disease (ND).
Both alcoholic and non-alcoholic lager beer drank in moderation can improve gut microbes in men – lessening the chances of developing chronic diseases.
Peter Bretscher, from the University of Saskatchewan looks at whether mouse models of cutaneous leishmaniasis are pertinent for vaccination against and treatment of AIDS, infectious diseases, and cancer.
Dr Roger J. Young, Professor at Saba University School of Medicine, walks us through Brittle Bone Disease, otherwise known as Osteogenesis Imperfecta Type I.
Dr. James E Goldman and Dr. Osama Al-Dalahmah from the Department of Pathology and Cell Biology at Columbia University, discuss the importance of brain banking from individuals with Huntington’s disease.
Pascale V Guillot, at the University College London, looks toward improving the quality of life for those with Osteogenesis imperfecta, a chronic health condition called brittle bone disease.
Research suggests that multisensory integration could be used as a novel marker for preclinical Alzheimer’s disease given reported associations between magnitude of visual-somatosensory integration and important cognitive and motor outcomes.
